Cotrimoxazole. Rationale for re-examining its indications for use.

  title={Cotrimoxazole. Rationale for re-examining its indications for use.},
  author={Robin A. Howe and Robert C. Spencer},
  journal={Drug safety},
  volume={14 4},
Trimethoprim was specifically developed in the late 1960s as a sulphonamide potentiator and was launched in combination with sulfamethoxazole as cotrimoxazole. Laboratory data showed synergy of antimicrobial action for the combination and suggested that the use of both agents would delay the emergence of resistance. However, the tissue distribution of trimethoprim and sulfamethoxazole does not favour synergy, and resistance among common pathogens to sulfamethoxazole is high. Clinical studies… CONTINUE READING